The role of the THY1 gene in human ovarian cancer suppression based on transfection studies

被引:42
作者
Abeysinghe, HR
Pollock, SJ
Guckert, NL
Veyberman, Y
Keng, P
Halterman, M
Federoff, HJ
Rosenblatt, JP
Wang, N
机构
[1] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Radiat Oncol, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Rochester, NY 14642 USA
[4] Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA
关键词
D O I
10.1016/S0165-4608(03)00234-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In our recent studies, the expression of the THY1 gene encoding a 25-28 kDa glycoprotein located at 11q23similar toq24, was found to be associated with complete tumor suppression of the ovarian cancer cell line SKOV-3 after the transfer of chromosome 11. These studies raised the possibility that THY1 maybe a candidate tumor suppressor gene for ovarian cancer. To investigate this, the complete cDNA sequence for THY1] was cloned and transfected into SKOV-3 ovarian cancer cells. The expression of THY1 in the transfectants was confirmed by Northern blot analysis, immunocytochemistry, and flow cytometry. Both SKOV-3-THY1 and SKOV-3-null cells were inoculated subcutaneously into severe combined immunodeficiency (SCID) mice to determine in vivo tumorigenicity. THY1 transfectants formed tumors, but overall tumor growth rate and tumor size was significantly reduced compared with their null counterparts. To further correlate THY1 expression with tumorigenicity, the THY1 antisense was transfected into the nontumorigenic clone, 11(C)9-8, which resulted in restoration of tumorigenicity. These data indicate that THY1 expression alone cannot suppress tumorigenicity; however, abrogation of THY1 expression from nontumorigenic cells can restore tumorigenesis. Taken together, the data suggest that THY1 is necessary but not sufficient to suppress ovarian tumorigenicity. Therefore, THY1 can be designated as a putative tumor suppressor gene for human ovarian cancer. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 23 条
[1]   THY1 expression is associated with tumor suppression of human ovarian cancer [J].
Abeysinghe, HR ;
Cao, Q ;
Xu, J ;
Pollock, S ;
Veyberman, Y ;
Guckert, NL ;
Keng, P ;
Wang, N .
CANCER GENETICS AND CYTOGENETICS, 2003, 143 (02) :125-132
[2]   ISOLATION AND PARTIAL CHARACTERIZATION OF THE HUMAN HOMOLOG OF THY-1 [J].
ADES, EW ;
ZWERNER, RK ;
ACTON, RT ;
BALCH, CM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 151 (02) :400-406
[3]  
Beissert S, 1998, J IMMUNOL, V161, P5296
[4]  
BONEWALD L, 1984, J IMMUNOGENET, V11, P283
[5]   CANCER STATISTICS, 1993 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) :7-26
[6]   ONCOGENESIS IN OVARIAN-CANCER [J].
BORRESEN, AL .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1992, 71 :25-30
[7]   IMMUNOHISTOCHEMICAL STUDIES OF THE ADULT HUMAN OVARY - POSSIBLE CONTRIBUTION OF IMMUNE AND EPITHELIAL FACTORS TO FOLLICULOGENESIS [J].
BUKOVSKY, A ;
KEENAN, JA ;
CAUDLE, MR ;
WIMALASENA, J ;
UPADHYAYA, NB ;
VANMETER, SE .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1995, 33 (04) :323-340
[8]   Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11 [J].
Cao, Q ;
Abeysinghe, H ;
Chow, O ;
Xu, J ;
Kaung, HL ;
Fong, CT ;
Keng, P ;
Insel, RA ;
Lee, WCM ;
Barrett, JC ;
Wang, N .
CANCER GENETICS AND CYTOGENETICS, 2001, 129 (02) :131-137
[9]  
CRAWFORD JM, 1986, LAB INVEST, V54, P122
[10]  
Gabra H, 1996, CANCER RES, V56, P950